医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Biodynamo, a Start-up, Develops ‘Demenice’, a Smart Watch That Prevents Dementia and Supports Daily Life of Patients with Dementia

2015年11月04日 PM10:00
このエントリーをはてなブックマークに追加


 

SEOUL, South Korea

Biodynamo Co. Ltd (www.biodynamo.net), a start-up developing medical and health solutions in Korea, announced that it developed a smart watch, ‘Demenice’ that prevents dementia and supports daily life of patients with dementia.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151104005651/en/

‘Demenice’ smart watch helps seniors in ages above 60 who have risks of dementia and its patients in early stage prevent and manage the disease by wearing it. The smart watch enables families of its wearers, dementia healthcare providers and dementia healthcare centers to monitor conditions of patients through smart phones or PCs and provide needed support to them based on data transmitted by the smart watch.

Featuring functions of early testing of dementia, cognitive therapy and management of medication, diet, exercise and wandering, ‘Demenice’ can prevent dementia and support daily life of patients with dementia.

Embedded with programs of cognitive rehabilitation treatment, medication management, dietary management, exercise management and location-tracking, the smart watch supports daily life of dementia patients and helps improvement of their symptoms. Among them, the wandering management program that tracks location can prevent missing of patients with dementia.

Biodynamo CEO James Eun said “Serious accidents caused by dementia is increasing, we developed ‘Demenice’ to help daily life of dementia patients and their families.”

Biodynamo developed ‘Demenice’ in collaboration with medical professionals specialized in dementia. Its investigational product is currently in clinical trial and it is scheduled to be launched in the first half of 2016.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151104005651/en/

CONTACT

Biodynamo
James Eun, 82-2-2241-3884
dmswogud@daum.net

同じカテゴリーの記事 

  • C2N Diagnostics Expands Into Japan Through Mediford Corporation Partnership With Precivity™ Blood Testing for Alzheimer’s Disease and Brain Research Market
  • BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report
  • Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
  • joimax® Obtains Registration for All Products in the Indian Market
  • Avistone Announces the Approval of Vebreltinib as the First MET-TKI Treatment for a Rare Brain Glioma Subtype in China